IPCA Labs Fact Sheet, IPCA Labs Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA Labs Fact Sheet    (IPLB)


Now or Never: Access Details of the No. 1 Small Cap Stock of 2020

Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.

IPCA LABS Price History

Price Rs 1,412.9
Mkt Cap Rs m 178,300
Vol '000 3.0
P/E X 28.1
P/CF X 28.5
EPS (TTM) Rs 50.3
% ch % 1.8
No. of shares m 126.20
% ch week % 4.0
% ch 1-mth % -1.6
% ch 12-mth % 45.6
52 week H/L Rs 1,615.7/844.2
(As on Apr 1, 2020 09:53:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

IPCA LABS Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
IPCA LABS EQUITY SHARE DATA
High Rs8998886436951,042 
Low Rs591629503400590 
Sales per share (Unadj.) Rs249.2230.3254.5260.2298.6 
Earnings per share (Unadj.) Rs20.17.615.419.035.0 
Diluted earnings per shareRs20.17.615.419.035.0 
Cash flow per share (Unadj.) Rs34.420.629.133.149.4 
Dividends per share (Unadj.) Rs1.0001.001.003.00 
Adj. dividends per shareRs1.000.001.001.003.00 
Dividend yield (eoy) %0.100.20.20.4 
Book value per share (Unadj.) Rs174.1179.0194.6213.0247.1 
Adj. book value per shareRs174.1179.0194.6213.0247.4 
Shares outstanding (eoy) m126.20126.20126.20126.20126.35 
Bonus/Rights/Conversions  ----ESOS 
Price / Sales ratio x3.03.32.32.12.7 
Avg P/E ratio x37.099.537.228.923.3 
P/CF ratio (eoy) x21.736.919.716.616.5 
Price / Book Value ratio x4.34.22.92.63.3 
Dividend payout %5.006.55.38.6 
Avg Mkt Cap Rs m94,05795,72372,30069,120103,108 
No. of employees `00013.013.113.313.313.4 
Total wages/salary Rs m5,6516,2566,9607,3597,874 
Avg. sales/employee Rs Th2,416.42,213.32,414.62,477.42,807.0 
Avg. wages/employee Rs Th434.3476.4523.2555.2585.8 
Avg. net profit/employee Rs Th195.473.3146.2180.6329.0 
IPCA LABS INCOME DATA
Net Sales Rs m31,44429,06532,12232,83637,732 
Other income Rs m327222210418577 
Total revenues Rs m31,77129,28732,33233,25438,309 
Gross profit Rs m5,3632,8964,3814,5056,901 
Depreciation Rs m1,7961,6331,7301,7771,824 
Interest Rs m284319241240189 
Profit before tax Rs m3,6111,1662,6212,9055,465 
Minority Interest Rs m00000 
Prior Period Items Rs m-490000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,0192046755111,042 
Profit after tax Rs m2,5429621,9452,3944,422 
Gross profit margin %17.110.013.613.718.3 
Effective tax rate %28.217.525.817.619.1 
Net profit margin %8.13.36.17.311.7 
IPCA LABS BALANCE SHEET DATA
Current assets Rs m19,34816,21917,41819,45523,778 
Current liabilities Rs m12,5179,7009,55910,07610,975 
Net working cap to sales %21.722.424.528.633.9 
Current ratio x1.51.71.81.92.2 
Inventory Days Days10710510098104 
Debtors Days Days7356576766 
Net fixed assets Rs m20,54021,42920,77920,43520,368 
Share capital Rs m252252252252253 
"Free" reserves Rs m21,56422,57824,30026,63330,971 
Net worth Rs m21,96522,59224,55326,88631,224 
Long term debt Rs m4,9874,8433,5172,3401,409 
Total assets Rs m41,24838,91739,59541,17345,507 
Interest coverage x13.74.711.913.130.0 
Debt to equity ratio x0.20.20.10.10 
Sales to assets ratio x0.80.70.80.80.8 
Return on assets %6.93.35.56.410.1 
Return on equity %11.64.37.98.914.2 
Return on capital %14.35.410.210.817.3 
Exports to sales %52.949.248.647.645.9 
Imports to sales %16.715.314.214.916.6 
Exports (fob) Rs m16,62414,29915,61715,64217,308 
Imports (cif) Rs m5,2474,4454,5714,8846,266 
Fx inflow Rs m16,74914,29915,61715,64217,308 
Fx outflow Rs m6,9565,8224,5714,8846,266 
Net fx Rs m9,7938,47711,04610,75911,042 
IPCA LABS CASH FLOW
From Operations Rs m 4,682 7,087 2,819 3,411 4,923 
From Investments Rs m -6,893 -2,183 -1,488 -1,354 -1,563 
From Financial Activity Rs m 2,505 -4,615 -1,591 -1,304 -1,832 
Net Cashflow Rs m 294 288 -260 753 1,528 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 45.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 11.4%
FIIs 25.3%
ADR/GDR 0.0%
Free float 17.4%
Shareholders 36,892
Pledged promoter(s) holding 2.1%
 

Company Information

REGD OFF 48, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067
E-MAIL investors@ipca.com WEB www.ipca.com
TELEPHONE (022) 6647 4444 FAX (022) 2868 6613
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
AUDITOR Natvarlal Vepari & Co.
CHM: Premchand Godha (MD) COMP SEC: Harish P. Kamath (VP - Legal) YEAR OF INC: 1949 BSE CODE: 524494 FV (Rs): 2 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   PROCTER & GAMBLE HEALTH  ORCHID PHARMA LTD  FRESENIUS KABI ONCO.  SUN PHARMA  NATCO PHARMA  

Compare IPCA LABS With:   PROCTER & GAMBLE HEALTH  ORCHID PHARMA LTD  FRESENIUS KABI ONCO.  SUN PHARMA  NATCO PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Telecom and Metal Stocks Fall(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.6% while the Hang Seng is down 0.6%.

Views on news

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON IPCA LABS

IPCA LABS - TEVA PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS